Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · Metalyse
Metalyse 8 000 units (40 mg) powder and solvent for solution for injection Metalyse 10 000 units (50 mg) powder and solvent for solution for injection · Abschnitt 4.3 · PDF-Seite 4
HOS-091175 · Präparat HOS-084225
- Significant bleeding disorder either at present or within the past 6 months
- Patients receiving effective oral anticoagulant treatment, (e.g. vitamin K antagonists with INR
> 1.3) (see section 4.4, subsection “Bleeding”)
- Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal
surgery)
- Known haemorrhagic diathesis
- Severe uncontrolled hypertension (see section 4.4)
- Major surgery, biopsy of a parenchymal organ, or significant trauma within the past 2 months
(this includes any trauma associated with the current AMI)
- Recent trauma to the head or cranium
- Bacterial endocarditis, pericarditis
- Acute pancreatitis
- Severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension
(oesophageal varices) and active hepatitis
- Active ulcerative gastro-intestinal disease
- Known arterial aneurysm and/or arterial/venous malformation
- Neoplasm with increased bleeding risk
- Any known history of haemorrhagic stroke or stroke of unknown origin
- Known history of ischaemic stroke or transient ischaemic attack in the preceding 6 months
- Dementia
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vitamin K (HOS-091176)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T11:27:00Z · SHA-256 48299a629b146e940b585aa86adeeb5c572a06d8c03ba539279d016f130efdea · Passage c32116ba52c7037edbb20c468dfb7f6777c083a18defce37ba606cc14874607c · Zeichen 510–1716 im Abschnitt
Gegenanzeigen · Metalyse
Metalyse 5 000 units (25 mg) powder for solution for injection · Abschnitt 4.3 · PDF-Seite 16
HOS-091193 · Präparat HOS-084225
- Significant bleeding disorder either at present or within the past 6 months
- Patients receiving effective anticoagulation (e.g. vitamin K antagonists with INR > 1.7) (see
section 4.4, subsection “Bleeding”)
- Known history of or suspected intracranial haemorrhage
- Symptoms suggestive of subarachnoid haemorrhage, even if CT-scan is normal
- Severe stroke as assessed clinically (e.g. NIHSS > 25) and/or by appropriate imaging techniques
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vitamin K (HOS-091176)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T11:27:00Z · SHA-256 48299a629b146e940b585aa86adeeb5c572a06d8c03ba539279d016f130efdea · Passage 31a62ad756ffe76cd5c3fa1684f0e761e99d8881341ecb2a9d52d9540b4dfe50 · Zeichen 304–789 im Abschnitt
Wechselwirkungen · Ceprotin
CEPROTIN 500 IU powder and solvent for solution for injection · Abschnitt 4.5 · PDF-Seite 5
HOS-091606 · Präparat HOS-084373
Interaction with Vitamin K antagonists
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vitamin K (HOS-091176)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-02-02T11:03:00Z · SHA-256 0185892452ffa6635104e46bba70ecf185fd6943b4e4c738d1e66a6dd19ed835 · Passage acfcd4ac6d8135f408157e27f98dd0104a2c3140ca140efed7d84266f9020a21 · Zeichen 68–106 im Abschnitt
Wechselwirkungen · Ceprotin
CEPROTIN 500 IU powder and solvent for solution for injection · Abschnitt 4.5 · PDF-Seite 5
HOS-091607 · Präparat HOS-084373
In patients starting treatment with oral anticoagulants belonging to the class of vitamin K antagonists
(e.g. warfarin), a transient hypercoagulable state may arise before the desired anticoagulant effect
becomes apparent. This transient effect may be explained by the fact that protein C, itself a vitamin K
dependent plasma protein, has a shorter half-life than most of the vitamin K dependent proteins
(i.e. II, IX and X). Subsequently, in the initial phase of treatment, the activity of protein C is more
rapidly suppressed than that of the procoagulant factors. For this reason, if the patient is switched to
oral anticoagulants, protein C replacement must be continued until stable anticoagulation is obtained.
Although Warfarin-induced skin necrosis can occur in any patient during the initiation of oral
anticoagulant therapy, individuals with congenital protein C deficiency are particularly at risk.
(See section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vitamin K (HOS-091176) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-02-02T11:03:00Z · SHA-256 0185892452ffa6635104e46bba70ecf185fd6943b4e4c738d1e66a6dd19ed835 · Passage 50220633d54f01d1050ba6008507e08834446629477e80758058087983443c06 · Zeichen 108–1036 im Abschnitt
Wechselwirkungen · Ceprotin
CEPROTIN 1,000 IU powder and solvent for solution for injection · Abschnitt 4.5 · PDF-Seite 13
HOS-091625 · Präparat HOS-084373
Interaction with Vitamin K antagonists
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vitamin K (HOS-091176)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-02-02T11:03:00Z · SHA-256 0185892452ffa6635104e46bba70ecf185fd6943b4e4c738d1e66a6dd19ed835 · Passage acfcd4ac6d8135f408157e27f98dd0104a2c3140ca140efed7d84266f9020a21 · Zeichen 68–106 im Abschnitt
Wechselwirkungen · Ceprotin
CEPROTIN 1,000 IU powder and solvent for solution for injection · Abschnitt 4.5 · PDF-Seite 13
HOS-091626 · Präparat HOS-084373
In patients starting treatment with oral anticoagulants belonging to the class of vitamin K antagonists
(e.g. warfarin), a transient hypercoagulable state may arise before the desired anticoagulant effect
becomes apparent. This transient effect may be explained by the fact that protein C, itself a vitamin
K dependent plasma protein, has a shorter half-life than most of the vitamin K dependent proteins
(i.e. II, IX and X). Subsequently, in the initial phase of treatment, the activity of protein C is more
rapidly suppressed than that of the procoagulant factors. For this reason, if the patient is switched to
oral anticoagulants, protein C replacement must be continued until stable anticoagulation is obtained.
Although Warfarin-induced skin necrosis can occur in any patient during the initiation of oral
anticoagulant therapy, individuals with congenital protein C deficiency are particularly at risk.
(See section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vitamin K (HOS-091176) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-02-02T11:03:00Z · SHA-256 0185892452ffa6635104e46bba70ecf185fd6943b4e4c738d1e66a6dd19ed835 · Passage 7298f1e3d8ee23306a49661d8634fa0571f5632d57a880a812537d83fb5fb3d8 · Zeichen 108–1036 im Abschnitt
Wechselwirkungen · Arixtra
Arixtra 1.5 mg/0.3 ml solution for injection, pre-filled syringe. · Abschnitt 4.5 · PDF-Seite 6
HOS-110102 · Präparat HOS-093307
Follow-up therapy with another anticoagulant medicinal product
If follow-up treatment is to be initiated with heparin or LMWH, the first injection should, as a general
rule, be given one day after the last fondaparinux injection.
If follow up treatment with a Vitamin K antagonist is required, treatment with fondaparinux should be
continued until the target INR value has been reached.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vitamin K (HOS-091176) heparin (HOS-086930)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T11:30:00Z · SHA-256 381af76ffd2bbb8fff8013d6d98ed50ab7a9f4fb8da38de9af66e45dcfd01fac · Passage 156e5588a0ba15a78bf42479a323e74e72bb3aace75c20482593e561e5de054d · Zeichen 626–1012 im Abschnitt
Wechselwirkungen · Arixtra
Arixtra 2.5 mg/0.5 ml solution for injection, pre-filled syringe. · Abschnitt 4.5 · PDF-Seite 19
HOS-110120 · Präparat HOS-093307
If follow up treatment with a Vitamin K antagonist is required, treatment with fondaparinux should be
continued until the target INR value has been reached.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vitamin K (HOS-091176)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T11:30:00Z · SHA-256 381af76ffd2bbb8fff8013d6d98ed50ab7a9f4fb8da38de9af66e45dcfd01fac · Passage abd53c86dbb631f63505866351b53d2c177049bf62d961d6c828e150e3f2e85b · Zeichen 857–1013 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 18
HOS-112098 · Präparat HOS-093615
Potential P-gp inhibition by REYATAZ is
unknown and cannot be excluded.
Edoxaban Potential for increased edoxaban Exercise caution when edoxaban is
concentrations which can result in a higher used with REYATAZ.
risk of bleeding. The mechanism of
interaction is P-gp inhibition by Please refer to the edoxaban SmPC
REYATAZ/ritonavir. sections 4.2 and 4.5 for appropriate
edoxaban dosage recommendations
Ritonavir is a strong P-gp inhibitor. for co-administration with P-gp
inhibitors.
Potential P-gp inhibition by REYATAZ is
unknown and cannot be excluded.
Vitamin K antagonists
Warfarin Co-administration with REYATAZ has the It is recommended that the
potential to increase or decrease warfarin International Normalised Ratio
concentrations. (INR) be monitored carefully
during treatment with REYATAZ,
especially when commencing
therapy.
ANTIEPILEPTICS
Carbamazepine REYATAZ may increase plasma levels of Carbamazepine in combination
carbamazepine due to CYP3A4 inhibition. with REYATAZ (with or without
ritonavir) is contraindicated due to
Due to carbamazepine inducing effect, a the risk for loss of virologic
reduction in REYATAZ exposure cannot response and development of
be ruled out. resistance (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) vitamin K (HOS-091176) edoxaban (HOS-086234) ritonavir (HOS-084521) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage c40a7a6266f785a25dbb354a07f91c94520c5a3d651618c940a1a9c837eb6fcf · Zeichen 41103–43352 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 53
HOS-112188 · Präparat HOS-093615
Potential P-gp inhibition by REYATAZ is
unknown and cannot be excluded.
Edoxaban Potential for increased edoxaban Exercise caution when
concentrations which can result in a higher edoxaban is used with
risk of bleeding. The mechanism of REYATAZ.
interaction is P-gp inhibition by
REYATAZ/ritonavir. Please refer to the edoxaban
SmPC sections 4.2 and 4.5 for
Ritonavir is a strong P-gp inhibitor. appropriate edoxaban dosage
recommendations for
Potential P-gp inhibition by REYATAZ is co-administration with P-gp
unknown and cannot be excluded. inhibitors.
Vitamin K antagonists
Warfarin Co-administration with REYATAZ has the It is recommended that the
potential to increase or decrease warfarin International Normalised Ratio
concentrations. (INR) be monitored carefully
during treatment with
REYATAZ, especially when
commencing therapy.
ANTIEPILEPTICS
Carbamazepine REYATAZ may increase plasma levels of Carbamazepine in combination
carbamazepine due to CYP3A4 inhibition. with REYATAZ (with or
without ritonavir) is
Due to carbamazepine inducing effect, a contraindicated due to the risk
reduction in REYATAZ exposure cannot for loss of virologic response
be ruled out. and development of resistance
(see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) vitamin K (HOS-091176) edoxaban (HOS-086234) ritonavir (HOS-084521) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 3c72b0d905c895d57fd010ae57e3be3340d1c57781ddd6896bebdffb442a9350 · Zeichen 41998–44483 im Abschnitt
Wechselwirkungen · Cholestagel
Cholestagel 625 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-112365 · Präparat HOS-093659
Anticoagulant therapy
Anticoagulant therapy should be monitored closely in patients receiving warfarin or similar agents,
since bile acid sequestrants, like Cholestagel, have been shown to reduce absorption of vitamin K and
therefore interfere with warfarin's anticoagulant effect. Specific clinical interaction studies with
colesevelam and vitamin K have not been performed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vitamin K (HOS-091176) colesevelam (HOS-112356) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-03T11:58:00Z · SHA-256 d40452a2cad7ddd7eafdc4661259cd69e3d231c506afe3b5edc5d67ea216dce5 · Passage d253ef8e3ae0f08f0f2250822dc18799f251102200061bffba89d30324021dff · Zeichen 1573–1948 im Abschnitt
Wechselwirkungen · Cholestagel
Cholestagel 625 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-112381 · Präparat HOS-093659
Other forms of interaction
Cholestagel did not induce any clinically significant reduction in the absorption of vitamins A, D, E or
K during clinical studies of up to one year. However, caution should be exercised when treating
patients with a susceptibility to vitamin K or fat-soluble vitamin deficiencies, such as patients with
malabsorption. In these patients, monitoring vitamin A, D and E levels and assessing vitamin K status
through the measurement of coagulation parameters is recommended and the vitamins should be
supplemented if necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vitamin K (HOS-091176) vitamin A (HOS-087475)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-03T11:58:00Z · SHA-256 d40452a2cad7ddd7eafdc4661259cd69e3d231c506afe3b5edc5d67ea216dce5 · Passage 87784de27f865458a1d63a765b7676de5ce8107f1475f7358f8857d6a19483ed · Zeichen 5789–6340 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 75 mg hard capsules · Abschnitt 4.5 · PDF-Seite 13
HOS-118650 · Präparat HOS-094855
There is no or only limited experience with the following treatments which may increase the risk of
bleeding when used concomitantly with dabigatran etexilate: anticoagulants such as unfractionated
heparin (UFH), low molecular weight heparins (LMWH), and heparin derivatives (fondaparinux,
desirudin), thrombolytic medicinal products, and vitamin K antagonists, rivaroxaban or other oral
anticoagulants (see section 4.3), and antiplatelet aggregation medicinal products such as GPIIb/IIIa
receptor antagonists, ticlopidine, prasugrel, ticagrelor, dextran, and sulfinpyrazone (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) sulfinpyrazone (HOS-089177) fondaparinux (HOS-110096) dextran (HOS-118654) vitamin K (HOS-091176) heparin (HOS-086930) rivaroxaban (HOS-086236) prasugrel (HOS-112066) desirudin (HOS-118651) ticlopidine (HOS-087946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage a2f6a9478f57630a4c855e173bebe15e2bee9f3bdbecaa93d3fe6350a29c6ded · Zeichen 8130–8723 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 110 mg hard capsules · Abschnitt 4.5 · PDF-Seite 46
HOS-118725 · Präparat HOS-094855
There is no or only limited experience with the following treatments which may increase the risk of
bleeding when used concomitantly with dabigatran etexilate: anticoagulants such as unfractionated
heparin (UFH), low molecular weight heparins (LMWH), and heparin derivatives (fondaparinux,
desirudin), thrombolytic medicinal products, and vitamin K antagonists, rivaroxaban or other oral
anticoagulants (see section 4.3), and antiplatelet aggregation medicinal products such as GPIIb/IIIa
receptor antagonists, ticlopidine, prasugrel, ticagrelor, dextran, and sulfinpyrazone (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) sulfinpyrazone (HOS-089177) fondaparinux (HOS-110096) dextran (HOS-118654) vitamin K (HOS-091176) heparin (HOS-086930) rivaroxaban (HOS-086236) prasugrel (HOS-112066) desirudin (HOS-118651) ticlopidine (HOS-087946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage a2f6a9478f57630a4c855e173bebe15e2bee9f3bdbecaa93d3fe6350a29c6ded · Zeichen 8103–8696 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 150 mg hard capsules · Abschnitt 4.5 · PDF-Seite 86
HOS-118814 · Präparat HOS-094855
There is no or only limited experience with the following treatments which may increase the risk of
bleeding when used concomitantly with dabigatran etexilate: anticoagulants such as unfractionated
heparin (UFH), low molecular weight heparins (LMWH), and heparin derivatives (fondaparinux,
desirudin), thrombolytic medicinal products, and vitamin K antagonists, rivaroxaban or other oral
anticoagulants (see section 4.3), and antiplatelet aggregation medicinal products such as GPIIb/IIIa
receptor antagonists, ticlopidine, prasugrel, ticagrelor, dextran, and sulfinpyrazone (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) sulfinpyrazone (HOS-089177) fondaparinux (HOS-110096) dextran (HOS-118654) vitamin K (HOS-091176) heparin (HOS-086930) rivaroxaban (HOS-086236) prasugrel (HOS-112066) desirudin (HOS-118651) ticlopidine (HOS-087946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage a2f6a9478f57630a4c855e173bebe15e2bee9f3bdbecaa93d3fe6350a29c6ded · Zeichen 8119–8712 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 20 mg coated granules Pradaxa 30 mg coated granules Pradaxa 40 mg coated granules Pradaxa 50 mg coated granules Pradaxa 110 mg coated granules Pradaxa 150 mg coated granules · Abschnitt 4.5 · PDF-Seite 120
HOS-118901 · Präparat HOS-094855
There is no or only limited experience with the following treatments which may increase the risk of
bleeding when used concomitantly with dabigatran etexilate: anticoagulants such as unfractionated
heparin (UFH), low molecular weight heparins (LMWH), and heparin derivatives (fondaparinux,
desirudin), thrombolytic medicinal products, and vitamin K antagonists, rivaroxaban or other oral
anticoagulants (see section 4.3), and antiplatelet aggregation medicinal products such as GPIIb/IIIa
receptor antagonists, ticlopidine, prasugrel, ticagrelor, dextran, and sulfinpyrazone (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) sulfinpyrazone (HOS-089177) fondaparinux (HOS-110096) dextran (HOS-118654) vitamin K (HOS-091176) heparin (HOS-086930) rivaroxaban (HOS-086236) prasugrel (HOS-112066) desirudin (HOS-118651) ticlopidine (HOS-087946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage a2f6a9478f57630a4c855e173bebe15e2bee9f3bdbecaa93d3fe6350a29c6ded · Zeichen 8244–8837 im Abschnitt
Wechselwirkungen · Bridion
Bridion 100 mg/mL solution for injection · Abschnitt 4.5 · PDF-Seite 7
HOS-119618 · Präparat HOS-094981
In a study in volunteers doses of 4 mg/kg and 16 mg/kg of sugammadex resulted in maximum mean
prolongations of aPTT by 17 and 22% respectively and of PT(INR) by 11 and 22% respectively.
These limited mean aPTT and PT(INR) prolongations were of short duration (≤ 30 minutes).
In in vitro experiments a pharmacodynamic interaction (aPTT and PT prolongation) was noted with
vitamin K antagonists, unfractionated heparin, low molecular weight heparinoids, rivaroxaban and
dabigatran (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vitamin K (HOS-091176) heparin (HOS-086930) dabigatran (HOS-112096) rivaroxaban (HOS-086236) heparinoids (HOS-119619)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-06T17:24:00Z · SHA-256 c678da8df4e0f062258fc41e9097613813dcaaecc8e8156e47a2d8252e6efd4e · Passage 135d9c06902241627f554d65e6f46425730be845dd850dccf7985e25d3c78098 · Zeichen 4832–5329 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-120052 · Präparat HOS-095079
Warfarin
Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or
from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin)
more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT,
inhibition of factor Xa activity and endogenous thrombin potential were additive.
If it is desired to test the pharmacodynamic effects of rivaroxaban during the conversion period, anti-
factor Xa activity, PiCT, and Heptest can be used as these tests were not affected by warfarin. On the
fourth day after the last dose of warfarin, all tests (including PT, aPTT, inhibition of factor Xa activity
and ETP) reflected only the effect of rivaroxaban.
If it is desired to test the pharmacodynamic effects of warfarin during the conversion period, INR
measurement can be used at the Ctrough of rivaroxaban (24 hours after the previous intake of
rivaroxaban) as this test is minimally affected by rivaroxaban at this time point.
No pharmacokinetic interaction was observed between warfarin and rivaroxaban.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): thrombin (HOS-120053) vitamin K (HOS-091176) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 918b34bc287cd79c46210954d3607f98f667e8a3885a27c80133167679b563d1 · Zeichen 4377–5482 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 35–36
HOS-120084 · Präparat HOS-095079
35
Warfarin
Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or
from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin)
more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT,
inhibition of factor Xa activity and endogenous thrombin potential were additive.
If it is desired to test the pharmacodynamic effects of rivaroxaban during the conversion period, anti-
factor Xa activity, PiCT, and Heptest can be used as these tests were not affected by warfarin. On the
fourth day after the last dose of warfarin, all tests (including PT, aPTT, inhibition of factor Xa activity
and ETP) reflected only the effect of rivaroxaban.
If it is desired to test the pharmacodynamic effects of warfarin during the conversion period, INR
measurement can be used at the Ctrough of rivaroxaban (24 hours after the previous intake of
rivaroxaban) as this test is minimally affected by rivaroxaban at this time point.
No pharmacokinetic interaction was observed between warfarin and rivaroxaban.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): thrombin (HOS-120053) vitamin K (HOS-091176) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 3eff9c5ee0153bba5f74e257f41052f4172ca58adb2badf7a92c77d31768ee07 · Zeichen 4432–5541 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 15 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 62–63
HOS-120115 · Präparat HOS-095079
62
Warfarin
Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or
from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin)
more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT,
inhibition of factor Xa activity and endogenous thrombin potential were additive.
If it is desired to test the pharmacodynamic effects of rivaroxaban during the conversion period, anti-
factor Xa activity, PiCT, and Heptest can be used as these tests were not affected by warfarin. On the
fourth day after the last dose of warfarin, all tests (including PT, aPTT, inhibition of factor Xa activity
and ETP) reflected only the effect of rivaroxaban.
If it is desired to test the pharmacodynamic effects of warfarin during the conversion period, INR
measurement can be used at the Ctrough of rivaroxaban (24 hours after the previous intake of
rivaroxaban) as this test is minimally affected by rivaroxaban at this time point.
No pharmacokinetic interaction was observed between warfarin and rivaroxaban.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): thrombin (HOS-120053) vitamin K (HOS-091176) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage f0d8430536a876d8383030c2c936de5109133a48a28dbb7eb5a43ea7a405bed7 · Zeichen 4656–5765 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.